WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H206144
CAS#: 1130115-44-4 (free base)
Description: Donafenib, also known as CM-4307, is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
Hodoodo Cat#: H206144
Name: Donafenib
CAS#: 1130115-44-4 (free base)
Chemical Formula: C21H13D3ClF3N4O3
Exact Mass: 467.11
Molecular Weight: 467.848
Elemental Analysis: C, 53.91; H, 4.09; Cl, 7.58; F, 12.18; N, 11.98; O, 10.26
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1130115-44-4 (free base) Donafenib mesylate
Synonym: Donafenib; CM-4307; CM 4307; CM4307.
IUPAC/Chemical Name: 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)-2-pyridinecarboxamide
InChi Key: MLDQJTXFUGDVEO-FIBGUPNXSA-N
InChi Code: InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3
SMILES Code: O=C(C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C=C2)=C1)NC([2H])([2H])[2H]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 467.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ho V, Lim TS, Lee J, Steinberg J, Szmyd R, Tham M, Yaligar J, Kaldis P, Abastado JP, Chew V. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Oncotarget. 2015 Jul 23. [Epub ahead of print] PubMed PMID: 26287667.
2: Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer. 2014 Oct;3(3-4):405-16. doi: 10.1159/000343861. Review. PubMed PMID: 26280002; PubMed Central PMCID: PMC4531424.
3: Kudo M. Biomarkers and Personalized Sorafenib Therapy. Liver Cancer. 2014 Oct;3(3-4):399-404. doi: 10.1159/000343870. PubMed PMID: 26280001; PubMed Central PMCID: PMC4531426.
4: Erika G, Federica Z, Martina S, Anselmo P, Luigi R, Marina M, Davide C, Eleonora Z, Monica V, Silverio T. Old tyrosine kinase inhibitors and newcomers in gastrointestinal cancer treatment. Curr Cancer Drug Targets. 2015 Aug 17. [Epub ahead of print] PubMed PMID: 26278713.
5: Liu JY, Chiang T, Liu CH, Chern GG, Lin TT, Gao DY, Chen Y. Delivery of siRNA using CXCR4-Targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Anti-Tumor Response in Liver Cancer. Mol Ther. 2015 Aug 17. doi: 10.1038/mt.2015.147. [Epub ahead of print] PubMed PMID: 26278330.
6: Huang J, Yan L, Wu H, Yang J, Liao M, Zeng Y. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res. 2015 Jul 28. pii: S0022-4804(15)00807-0. doi: 10.1016/j.jss.2015.07.033. [Epub ahead of print] PubMed PMID: 26277218.
7: Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS One. 2015 Aug 14;10(8):e0134731. doi: 10.1371/journal.pone.0134731. eCollection 2015. PubMed PMID: 26275293.
8: Jiang E, Shangguan AJ, Chen S, Tang L, Zhao S, Yu Z. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. Cancer Lett. 2015 Aug 10. pii: S0304-3835(15)00471-1. doi: 10.1016/j.canlet.2015.07.016. [Epub ahead of print] PubMed PMID: 26272181.
9: Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice? Future Oncol. 2015 Aug 13:1-3. [Epub ahead of print] PubMed PMID: 26270206.
10: Ch'ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol. 2015 Aug 8;7(16):2029-40. doi: 10.4254/wjh.v7.i16.2029. Review. PubMed PMID: 26261692; PubMed Central PMCID: PMC4528276.
